TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6/14/24 16:26 | 6/12/24 | DNA | Ginkgo Bioworks Holdings, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Belldegrun Arie | MA | D | M.d | 0 | 0.00 | 0 | 105 | 18 | 695 | D | |||||||||||||||
5/20/24 21:33 | 5/16/24 | ALLO | Allogene Therapeutics, Inc. | Health | BioPrd | Biological Products, (No Diag | Belldegrun Arie | CA | D | P | 5,000 | 2.90 | 0 | 1,724 | 21 | 10,099 | I | ||||||||||||||||
9/16/22 15:13 | 9/14/22 | URGN | Urogen Pharma Ltd. | L3 | Health | Drug | Pharmaceutical Preparations | Belldegrun Arie | NJ | D | M.d | 800 | 5.00 | 0 | 160 | 64 | 409 | D | |||||||||||||||
9/2/22 11:40 | 8/31/22 | URGN | Urogen Pharma Ltd. | L3 | Health | Drug | Pharmaceutical Preparations | Belldegrun Arie | NJ | D | M.d | 16 | 5.00 | 0 | 3 | 1 | 249 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |